Vasopressin hormone (argipressin)

Vasopressin hormone (argipressin) is filed as Vasopressin. The sections below restate public label fields stored for this profile.

Class
Vasopressin
Generic name
argipressin
Route
INTRAVENOUS
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Vasopressin Injection, USP is a clear, practically colorless solution for intravenous administration available as 20 units/mL in a single dose vial. To be used after dilution. Injection: 20 units per mL in a single dose vial. To be used after dilution. ( 3 )
Manufacturer
Amphastar Pharmaceuticals, Inc.

How it works

12.1 Mechanism of Action Vasopressin causes vasoconstriction by binding to V 1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V 2 receptors which are coupled to adenyl cyclase.

Contraindications

4 CONTRAINDICATIONS Vasopressin Injection, USP 1 mL single dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol. Vasopressin Injection, USP 1 mL single dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol. ( 4 )

Common side effects

Decreased cardiac output (Common); Bradycardia (Common); Tachyarrhythmias (Common); Hyponatremia (Common); Ischemia (coronary (Common); Mesenteric (Common); Skin (Common); Digital) (Common)

Adverse reactions

6 ADVERSE REACTIONS The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia Gastrointestinal disorders: Mesenteric ischemia Hepatobiliary: Increased bilirubin levels Renal/urinary disorders: Acute renal insufficiency Vascular disorders: Distal limb ischemia Metabolic: Hyponatremia Skin: Ischemic lesions Postmarketing Experience Reversible diabetes insipidus [ see Warnings and Precautions ( 5.2 ) ]. The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Amphastar Pharmaceuticals, Inc. at 1-800-423-4136 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Dosage and administration

2 DOSAGE AND ADMINISTRATION Dilute 20 units/mL, single dose vial contents with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. ( 2.1 ) Post-cardiotomy shock: 0.03 to 0.1 units/minute ( 2.2 ) Septic shock: 0.01 to 0.07 units/minute ( 2.2 ) 2.1 Preparation of Solution Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit. Dilute Vasopressin Injection, USP in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. Table 1 Preparation of diluted solutions Fluid restriction? Final concentration Mix Vasopressin Injection, USP Diluent No 0.1 units/mL 2.5 mL (50 units) 500 mL Yes 1 unit/mL 5 mL (100 units) 100 mL 2.2 Administration In general, titrate to the lowest dose compatible with a clinically acceptable response. The recommended starting dose is: Post-cardiotomy shock: 0.03 units/minute Septic Shock: 0.01 units/minute Tritate up by 0.005 units/minute at 10- to 15-minute intervals until the target blood pressure is reached. There are limited data for doses above 0.1 units/minute for post-cardiotomy shock and 0.07 units/minute for septic shock. Adverse reactions are expected to increase with higher doses. After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin injection by 0.005 units/minute every hour as tolerated to maintain target blood pressure.

Drug interactions

7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin Injection, USP are expected to be additive. ( 7.1 ) Indomethacin may prolong effects of Vasopressin Injection, USP. ( 7.2 ) Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response. ( 7.3 , 7.5 ) Co-administration of drugs causing diabetes insipidus may decrease the pressor response. ( 7.6 ) 7.1 Catecholamines Use with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin Injection, USP on cardiac index and systemic vascular resistance. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [see Clinical Pharmacology ( 12.3 ) ]. 7.3 Ganglionic Blocking Agents Use with ganglionic blocking agents may increase the effect of Vasopressin Injection, USP on mean arterial blood pressure. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [ see Clinical Pharmacology ( 12.3 ) ]. 7.4 Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin Injection, USP. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed. 7.5 Drugs Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin Injection, USP. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

Common questions

What class of drug is Vasopressin hormone?

Vasopressin hormone (argipressin) belongs to the Vasopressin class of medications.

What form does Vasopressin hormone come in?

The FDA label lists Vasopressin hormone (argipressin) as: 3 DOSAGE FORMS AND STRENGTHS Vasopressin Injection, USP is a clear, practically colorless solution for intravenous administration available as 20 units/mL in a single dose vial. To be used after dilution. Injection: 20 units per mL in a single dose vial. To be used after dilution. ( 3 ); intravenous route. Available strengths and packaging vary by manufacturer.

Does Vasopressin hormone have a Boxed Warning?

Our ingest of the FDA label for Vasopressin hormone (argipressin) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Vasopressin hormone currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Vasopressin hormone (argipressin) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Vasopressin hormone approved by the FDA?

The FDA record lists the approval date for Vasopressin hormone (argipressin) as 2022-07-18.

Who makes Vasopressin hormone?

The FDA label lists Amphastar Pharmaceuticals, Inc. as a labeler/manufacturer of Vasopressin hormone (argipressin). Multiple firms may market generics of the same molecule.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…